I did a drug interaction checker for you.
Interactions between your selected drugs
simvastatin ↔ fenofibrate
Applies to: simvastatin, fenofibrate
GENERALLY AVOID: Severe myopathy and rhabdomyolysis have been reported during concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives, especially gemfibrozil. Gemfibrozil has been reported to significantly increase the plasma concentrations of some HMG-CoA reductase inhibitors and/or their active metabolites, including lovastatin, simvastatin, pravastatin, cerivastatin, and rosuvastatin (but not fluvastatin). High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death. Other fibrates have not been shown to significantly affect the pharmacokinetics of HMG-CoA reductase inhibitors. However, the use of fibrates alone has also been associated with development of myopathy, thus a pharmacodynamic interaction could conceivably occur.
MANAGEMENT: Concurrent use of fibric acid derivatives and HMG-CoA reductase inhibitors should generally be avoided unless the benefit of further alterations in lipid levels is anticipated to outweigh the potential risks. Addition of fibrates to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained. If the combination is prescribed, a fibrate other than gemfibrozil may be preferable, along with lower initial dosages of the HMG-CoA reductase inhibitor. If gemfibrozil is used, simvastatin and rosuvastatin daily dosage should not exceed 10 mg. Lovastatin labeling recommends that the dosage not exceed 20 mg daily when prescribed with gemfibrozil or other fibrates. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.
Other drugs that your selected drugs interact with
* fenofibrate interacts with more than 50 other drugs.
* simvastatin interacts with more than 100 other drugs.
CHOLESTEROL FIGHTER ORAL
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction
Whats this means, I don't know. Other then they should not be taking togeather.
The CHOLESTEROL Med does not act well either of the other two.
- Simvastatin Information for Consumers
- Simvastatin Information for Healthcare Professionals (includes dosage details)
- Side Effects of Simvastatin (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 28 May 2010 • 1 answer
Posted 29 Jun 2010 • 1 answer
Posted 14 Apr 2011 • 2 answers
Posted 23 Jun 2011 • 1 answer
Posted 1 Nov 2012 • 1 answer